Skye Bioscience reports Q3 EPS (32c), consensus (32c)

“As we obtain additional data from our CBeyond Phase 2a study, a holistic review provides us with additional confidence that nimacimab’s biology is active and has the potential to fill notable gaps in the obesity and overweight landscape in order to support a healthier weight loss journey for patients,” said Punit Dhillon, President & CEO of Skye. “With the positive combination data, we are shifting our focus to a combination development pathway while simultaneously planning to further understand nimacimab’s potential benefit in a monotherapy setting. We anticipate that forthcoming biomarker data and the readout from the 26-week extension will continue to build upon this story and provide further insights into nimacimab’s full potential as a metabolic therapy.”